Access the full text.
Sign up today, get DeepDyve free for 14 days.
James Bogenberger, D. Delman, Nanna Hansen, R. Valdez, V. Fauble, R. Mesa, R. Tibes (2015)Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies
Leukemia & Lymphoma, 56
N Gangat (2016)76
Am J Hematol, 91
A. Wei, S. Strickland, G. Roboz, Jingzhou Hou, W. Fiedler, T. Lin, R. Walter, A. Enjeti, B. Chyla, R. Popovic, Kaffa Fakouhi, P. Shah, M. Dunbar, T. Xu, M. Mabry, J. Hayslip (2017)Phase 1/2 Study of Venetoclax with Low-Dose Cytarabine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy: 1-Year Outcomes
E. Papaemmanuil, M. Gerstung, L. Malcovati, S. Tauro, G. Gundem, P. Loo, Christopher Yoon, Peter Ellis, D. Wedge, A. Pellagatti, A. Shlien, M. Groves, S. Forbes, K. Raine, Jonathon Hinton, L. Mudie, Stuart Mclaren, Claire Hardy, Calli Latimer, M. Porta, S. O'meara, Ilaria Ambaglio, A. Gallì, A. Butler, G. Walldin, J. Teague, L. Quek, A. Sternberg, C. Gambacorti-Passerini, N. Cross, A. Green, J. Boultwood, P. Vyas, E. Hellstrom-Lindberg, D. Bowen, M. Cazzola, M. Stratton, P. Campbell (2013)Clinical and biological implications of driver mutations in myelodysplastic syndromes.
Blood, 122 22
I. Kouchkovsky, M. Abdul-Hay (2016)‘Acute myeloid leukemia: a comprehensive review and 2016 update'
Blood Cancer Journal, 6
MA Sekeres (2010)287
Hematol Oncol Clin North Am, 24
C. Dinardo, K. Pratz, A. Letai, B. Jonas, A. Wei, M. Thirman, M. Arellano, M. Frattini, H. Kantarjian, R. Popovic, B. Chyla, T. Xu, M. Dunbar, S. Agarwal, R. Humerickhouse, M. Mabry, J. Potluri, M. Konopleva, D. Pollyea (2018)Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
The Lancet. Oncology, 19 2
G. Juliusson, P. Antunović, A. Derolf, S. Lehmann, L. Möllgård, D. Stockelberg, U. Tidefelt, A. Wåhlin, M. Höglund (2009)Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry.
Blood, 113 18
G. Marcucci, K. Maharry, S. Whitman, T. Vukosavljevic, P. Paschka, C. Langer, K. Mrózek, C. Baldus, A. Carroll, B. Powell, J. Kolitz, R. Larson, C. Bloomfield (2007)High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 22
A. Ashkenazi, W. Fairbrother, J. Leverson, A. Souers (2017)From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors
Nature Reviews Drug Discovery, 16
James Bogenberger, Clifford Whatcott, Nanna Hansen, D. Delman, C. Shi, Wontak Kim, Hillary Haws, Katherine Soh, Y. Lee, P. Peterson, Adam Siddiqui-Jain, S. Weitman, K. Stewart, D. Bearss, R. Mesa, S. Warner, R. Tibes (2017)Combined venetoclax and alvocidib in acute myeloid leukemia
Y. Tsujimoto, L. Finger, J. Yunis, P. Nowell, C. Croce (1984)Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation.
Science, 226 4678
D. Banker, J. Radich, Abram Becker, K. Kerkof, T. Norwood, C. Willman, F. Appelbaum (1998)The t(8;21) translocation is not consistently associated with high Bcl-2 expression in de novo acute myeloid leukemias of adults.
Clinical cancer research : an official journal of the American Association for Cancer Research, 4 12
A. Ashkenazi, V. Dixit (1998)Death receptors: signaling and modulation.
Science, 281 5381
E. Lagadinou, Alexander Šach, K. Callahan, R. Rossi, S. Neering, Mohammad Minhajuddin, J. Ashton, Shanshan Pei, Valerie Grose, K. O'Dwyer, J. Liesveld, P. Brookes, M. Becker, C. Jordan (2013)BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells.
Cell stem cell, 12 3
K. Mason, M. Carpinelli, J. Fletcher, J. Collinge, Adrienne Hilton, S. Ellis, Priscilla Kelly, P. Ekert, D. Metcalf, A. Roberts, D. Huang, B. Kile (2007)Programmed Anuclear Cell Death Delimits Platelet Life Span
G. Marcucci, J. Byrd, G. Dai, M. Klisovic, P. Kourlas, D. Young, S. Cataland, D. Fisher, D. Lucas, K. Chan, P. Porcu, Zhong Lin, Sherif Farag, S. Frankel, J. Zwiebel, E. Kraut, S. Balcerzak, C. Bloomfield, M. Grever, M. Caligiuri (2003)Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia.
Blood, 101 2
M. Arellano, G. Borthakur, M. Berger, J. Luer, A. Raza (2014)A phase II, multicenter, open-label study of obatoclax mesylate in patients with previously untreated myelodysplastic syndromes with anemia or thrombocytopenia.
Clinical lymphoma, myeloma & leukemia, 14 6
L. Rosiñol, A. Oriol, R. Ríos, A. Sureda, M. Blanchard, M. Hernandez, R. Martínez-Martínez, J. Moraleda, I. Jarque, J. Bargay, M. Gironella, M. Moreno, L. Palomera, Y. Gonzalez-Montes, J. Martí, I. Krsnik, J. Arguiñano, Maria-Esther Gonzalez, A. Gonzalez, F. Casado, L. López-Anglada, B. Paiva, M. Mateos, J. Miguel, J. Lahuerta, J. Bladé (2017)Bortezomib, Lenalidomide and Dexamethasone (VRD-GEM) As Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM): Results of a Prospective Phase III Pethema/GEM Trial
T. Tauchi, S. Okabe, S. Katagiri, Yuko Tanaka, K. Ohyashiki (2017)Combining Effects of the SMO Inhibitor and BCL-2 Inhibitor in MDS-Derived Induced Potent Stem Cells (iPSC)
Tzu-Chieh Ho, M. LaMere, Brett Stevens, J. Ashton, Jason Myers, K. O'Dwyer, J. Liesveld, J. Mendler, M. Guzman, J. Morrissette, Jianhua Zhao, E. Wang, M. Wetzler, C. Jordan, M. Becker (2013)Evolution of acute myelogenous leukemia stem cell properties after treatment and progression.
Blood, 128 13
J. Warner, Jean Wang, Kristin Hope, Liqing Jin, J. Dick (2004)Concepts of human leukemic development
A. Schimmer, A. Raza, T. Carter, D. Claxton, H. Erba, D. DeAngelo, M. Tallman, C. Goard, G. Borthakur (2014)A Multicenter Phase I/II Study of Obatoclax Mesylate Administered as a 3- or 24-Hour Infusion in Older Patients with Previously Untreated Acute Myeloid Leukemia
PLoS ONE, 9
James Bogenberger, S. Kornblau, W. Pierceall, Ryan Lena, Donald Chow, C. Shi, J. Mantei, G. Ahmann, Irma Gonzales, A. Choudhary, R. Valdez, J. Camoriano, V. Fauble, R. Tiedemann, R. Tiedemann, Y. Qiu, K. Coombes, M. Cardone, E. Braggio, H. Yin, D. Azorsa, R. Mesa, A. Stewart, R. Tibes (2014)BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies
N. Danial, S. Korsmeyer (2004)Cell Death Critical Control Points
R. Invernizzi, A. Pecci, L. Bellotti, E. Ascari (2001)Expression of p53, Bcl-2 and Ras Oncoproteins and Apoptosis Levels in Acute Leukaemias and Myelodysplastic Syndromes
Leukemia & Lymphoma, 42
John Reed (1997)Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies.
Seminars in hematology, 34 4 Suppl 5
PL Greenberg (2012)2454
R. Rajapaksa, N. Ginzton, L. Rott, P. Greenberg (1996)Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells
D. Vaux, S. Cory, Jerry Adams (1988)Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells
E. Estey (2001)Therapeutic options for acute myelogenous leukemia
Xiaojia Niu, Jianyun Zhao, Jun Ma, C. Xie, Holly Edwards, Guan Wang, J. Caldwell, Shengyan Xiang, X. Zhang, R. Chu, Z. Wang, Hai Lin, J. Taub, J. Taub, Y. Ge (2016)Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells
Clinical Cancer Research, 22
R. Mali, E. Lasater, K. Doyle, Ritu Malla, E. Boghaert, A. Souers, J. Leverson, D. Sampath (2018)Abstract B052: FLT3-ITD activation mediates resistance to the BCL-2 selective antagonist, venetoclax, in FLT3-ITD mutant AML models
Molecular Cancer Therapeutics, 17
P. Greenberg, H. Tuechler, J. Schanz, G. Sanz, G. Garcia-Manero, F. Solé, J. Bennett, D. Bowen, P. Fenaux, F. Dreyfus, H. Kantarjian, A. Kuendgen, A. Levis, L. Malcovati, M. Cazzola, J. Čermák, C. Fonatsch, M. Beau, M. Slovak, O. Krieger, M. Luebbert, J. Maciejewski, S. Magalhães, Y. Miyazaki, M. Pfeilstöcker, M. Sekeres, W. Sperr, R. Stauder, S. Tauro, P. Valent, T. Vallespí, A. Loosdrecht, U. Germing, D. Haase (2012)Revised international prognostic scoring system for myelodysplastic syndromes.
Blood, 120 12
M. Leisch, Bettina Jansko, N. Zaborsky, R. Greil, L. Pleyer (2019)Next Generation Sequencing in AML—On the Way to Becoming a New Standard for Treatment Initiation and/or Modulation?
S. Schoenwaelder, K. Jarman, E. Gardiner, M. Hua, J. Qiao, Michael White, E. Josefsson, I. Alwis, A. Ono, A. Willcox, R. Andrews, K. Mason, H. Salem, D. Huang, B. Kile, A. Roberts, S. Jackson (2011)Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets.
Blood, 118 6
D. Pollyea, C. Jordan (2017)Therapeutic targeting of acute myeloid leukemia stem cells.
Blood, 129 12
Haiming Dai, Wei Meng, ScottH Kaufmann (2016)BCL2 Family, Mitochondrial Apoptosis, and Beyond
Cancer Translational Medicine, 2
S. Jilg, Veronika Reidel, C. Müller-Thomas, J. König, J. Schauwecker, Ulrike Höckendorf, C. Huberle, O. Gorka, B. Schmidt, R. Burgkart, J. Ruland, H. Kolb, C. Peschel, R. Oostendorp, K. Götze, P. Jost (2016)Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients
Zhaoyu Jin, W. El-Deiry (2005)Overview of cell death signaling pathways
Cancer Biology & Therapy, 4
S. Corey, M. Minden, D. Barber, H. Kantarjian, Jean Wang, A. Schimmer (2007)Myelodysplastic syndromes: the complexity of stem-cell diseases
Nature Reviews Cancer, 7
A. Schimmer, S. O'Brien, H. Kantarjian, J. Brandwein, B. Cheson, M. Minden, K. Yee, F. Ravandi, F. Giles, A. Schuh, Vikas Gupta, M. Andreeff, C. Koller, Hong Chang, S. Kamel‐Reid, M. Berger, J. Viallet, G. Borthakur (2008)A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies
Clinical Cancer Research, 14
L. Campos, J. Rouault, O. Sabido, P. Oriol, N. Roubi, C. Vasselon, E. Archimbaud, J. Magaud, D. Guyotat (1993)High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy.
Blood, 81 11
G. Marcucci, B. Moser, W. Blum, W. Stock, M. Wetzler, J. Kolitz, M. Thakuri, T. Carter, R. Stuart, R. Larson (2007)A phase III randomized trial of intensive induction and consolidation chemotherapy ± oblimersen, a pro-apoptotic Bcl-2 antisense oligonucleotide in untreated acute myeloid leukemia patients >60 years old
Journal of Clinical Oncology, 25
R. Mali, E. Lasater, K. Doyle, Ritu Malla, E. Boghaert, A. Souers, J. Leverson, D. Sampath (2017)FLT3-ITD Activation Mediates Resistance to the BCL-2 Selective Antagonist, Venetoclax, in FLT3-ITD Mutant AML Models
C. Dinardo, C. Rausch, C. Benton, T. Kadia, N. Jain, N. Pemmaraju, N. Daver, Wendy Covert, K. Marx, M. Mace, E. Jabbour, J. Cortes, G. Garcia-Manero, F. Ravandi, K. Bhalla, H. Kantarjian, M. Konopleva (2018)Clinical experience with the BCL2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies
American Journal of Hematology, 93
T. Tsao, Yue-xi Shi, S. Kornblau, Hongbo Lu, S. Konoplev, Ansu Antony, V. Ruvolo, Y. Qiu, Ninaxiang Zhang, K. Coombes, M. Andreeff, K. Kojima, M. Konopleva (2012)Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells
Annals of Hematology, 91
Haichao Zhang, Paul Nimmer, S. Tahir, Jun Chen, R. Fryer, K. Hahn, L. Iciek, S. Morgan, M. Nasarre, R. Nelson, L. Preusser, G. Reinhart, Morey Smith, S. Rosenberg, S. Elmore, Chris Tse (2007)Bcl-2 family proteins are essential for platelet survival
Cell Death and Differentiation, 14
J. Parker, G. Mufti, Feyrooz Rasool, A. Mijovic, S. Devereux, A. Pagliuca (2000)The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS.
Blood, 96 12
R. Youle, A. Strasser (2008)The BCL-2 protein family: opposing activities that mediate cell death
Nature Reviews Molecular Cell Biology, 9
Claudia Bruedigam, F. Bagger, F. Heidel, C. Kuhn, Solene Guignes, A. Song, R. Austin, T. Vu, Erwin Lee, Sarbjit Riyat, A. Moore, R. Lock, L. Bullinger, G. Hill, S. Armstrong, David Williams, S. Lane (2014)Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy.
Cell stem cell, 15 6
Joshua Rusbuldt, L. Luistro, D. Chin, M. Smith, A. Wong, Margarita Romero, A. Rizo, J. Bussolari, F. Huang, A. Sasser (2017)Abstract 1101: Telomerase inhibitor imetelstat in combination with the BCL-2 inhibitor venetoclax enhances apoptosisin vitroand increases survivalin vivoin acute myeloid leukemia
Cancer Research, 77
Rongqing Pan, V. Ruvolo, Jun Wei, M. Konopleva, John Reed, M. Pellecchia, M. Andreeff, P. Ruvolo (2015)Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.
Blood, 126 3
Chris Tse, A. Shoemaker, Jessica Adickes, Mark Anderson, Jun Chen, Sha Jin, Eric Johnson, K. Marsh, M. Mitten, Paul Nimmer, Lisa Roberts, S. Tahir, Yu Xiao, Xiufen Yang, Haichao Zhang, S. Fesik, S. Rosenberg, S. Elmore (2008)ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.
Cancer research, 68 9
M. Cleary, Stephen Smith, J. Sklar (1986)Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation
M. Sekeres (2010)The epidemiology of myelodysplastic syndromes.
Hematology/oncology clinics of North America, 24 2
K. Kojima, M. Konopleva, I. Samudio, W. Schober, W. Bornmann, M. Andreeff (2006)Concomitant Inhibition of MDM2 and Bcl-2 Protein Function Synergistically Induce Mitochondrial Apoptosis in AML
Cell Cycle, 5
M. Konopleva, A. Tari, Z. Estrov, D. Harris, Z. Xie, Shourong Zhao, G. Lopez-Berestein, M. Andreeff (2000)Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins.
Blood, 95 12
J. Moore, K. Seiter, J. Kolitz, W. Stock, F. Giles, M. Kalaycio, D. Zenk, G. Marcucci (2006)A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse.
Leukemia research, 30 7
A. Ebrahim, M. Kandouz, Allison Liddane, H. Sabbagh, Yuning Hou, Chunying Li, A. Al-Katib (2016)PNT2258, a novel deoxyribonucleic acid inhibitor, induces cell cycle arrest and apoptosis via a distinct mechanism of action: a new class of drug for non-Hodgkin's lymphoma
M. Konopleva, D. Pollyea, J. Potluri, B. Chyla, L. Hogdal, T. Busman, E. Mckeegan, A. Salem, Ming Zhu, J. Ricker, W. Blum, C. Dinardo, T. Kadia, M. Dunbar, R. Kirby, N. Falotico, J. Leverson, R. Humerickhouse, M. Mabry, R. Stone, H. Kantarjian, A. Letai (2016)Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.
Cancer discovery, 6 10
M. Konopleva, R. Contractor, T. Tsao, I. Samudio, P. Ruvolo, S. Kitada, Xingming Deng, D. Zhai, Yue-xi Shi, T. Sneed, M. Verhaegen, M. Soengas, V. Ruvolo, T. McQueen, W. Schober, J. Watt, T. Jiffar, Xiaoyang Ling, F. Marini, D. Harris, M. Dietrich, Z. Estrov, J. McCubrey, W. May, John Reed, M. Andreeff (2006)Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia.
Cancer cell, 10 5
H. Wang, John Reed (1998)Mechanisms of Bcl-2 protein function.
Histology and histopathology, 13 2
N. Daver, D. Pollyea, K. Yee, P. Fenaux, J. Brandwein, N. Vey, G. Martinelli, K. Kelly, G. Roboz, Jacqueline Garcia, A. Pigneux, S. Kshirsagar, Monique Dail, Jue Wang, M. Mobasher, Lin-Chi Chen, W. Hong, M. Konopleva, M. Andreeff (2017)Preliminary Results from a Phase Ib Study Evaluating BCL-2 Inhibitor Venetoclax in Combination with MEK Inhibitor Cobimetinib or MDM2 Inhibitor Idasanutlin in Patients with Relapsed or Refractory (R/R) AML
Steven Chan, Daniel Thomas, M. Corces-Zimmerman, Seethu Xavy, S. Rastogi, W. Hong, Feifei Zhao, Bruno Medeiros, David Tyvoll, R. Majeti (2015)Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia
Nature Medicine, 21
G. Marcucci, W. Stock, G. Dai, R. Klisovic, Shujun Liu, M. Klisovic, W. Blum, C. Kefauver, D. Sher, Margaret Green, M. Moran, K. Maharry, S. Novick, C. Bloomfield, J. Zwiebel, R. Larson, M. Grever, K. Chan, J. Byrd (2005)Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 15
J. Schanz, H. Tüchler, F. Solé, M. Mallo, E. Luño, J. Cervera, I. Granada, B. Hildebrandt, M. Slovak, K. Ohyashiki, C. Steidl, C. Fonatsch, M. Pfeilstöcker, T. Nösslinger, P. Valent, A. Giagounidis, C. Aul, M. Lübbert, R. Stauder, O. Krieger, G. Garcia-Manero, S. Faderl, S. Pierce, M. Beau, J. Bennett, P. Greenberg, U. Germing, D. Haase (2012)New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 8
B. Ball, A. Zeidan, S. Gore, T. Prebet (2017)Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings
Leukemia & Lymphoma, 58
D. Baev, J. Krawczyk, M. O'Dwyer, E. Szegezdi (2014)The BH3-mimetic ABT-737 effectively kills acute myeloid leukemia initiating cells
Leukemia Research Reports, 3
W. Wilson, O. O’Connor, M. Czuczman, A. LaCasce, J. Gerecitano, J. Leonard, A. Tulpule, K. Dunleavy, H. Xiong, Y. Chiu, Yue Cui, T. Busman, S. Elmore, S. Rosenberg, A. Krivoshik, S. Enschede, R. Humerickhouse (2010)Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity.
The Lancet. Oncology, 11 12
E Papaemmanuil (2013)3616
C. Dinardo, D. Pollyea, B. Jonas, M. Konopleva, V. Pullarkat, A. Wei, H. Kantarjian, A. Pigneux, C. Récher, J. Seymour, M. Dunbar, T. Xu, M. Mabry, J. Potluri, K. Pratz, A. Letai (2017)Updated Safety and Efficacy of Venetoclax with Decitabine or Azacitidine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia
Susu Zhang, Yue Zhao, Tiffany Heaster, Melissa Fischer, K. Stengel, Xiaofan Zhou, Haley Ramsey, Ming-Ming Zhou, M. Savona, M. Skala, S. Hiebert (2018)BET inhibitors reduce cell size and induce reversible cell cycle arrest in AML
Journal of Cellular Biochemistry, 120
N. Gangat, M. Patnaik, A. Tefferi (2016)Myelodysplastic syndromes: Contemporary review and how we treat
American Journal of Hematology, 91
F. Appelbaum, H. Gundacker, D. Head, M. Slovak, C. Willman, J. Godwin, J. Anderson, S. Petersdorf (2006)Age and acute myeloid leukemia.
Blood, 107 9
S. Kurtz, C. Eide, A. Kaempf, V. Khanna, S. Savage, Angela Rofelty, I. English, Hibery Ho, Ravi Pandya, W. Bolosky, Hoifung Poon, M. Deininger, R. Collins, R. Swords, J. Watts, D. Pollyea, B. Medeiros, E. Traer, C. Tognon, M. Mori, B. Druker, J. Tyner (2017)Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies
Proceedings of the National Academy of Sciences, 114
N. Yan, Yigong Shi (2005)Mechanisms of apoptosis through structural biology.
Annual review of cell and developmental biology, 21
D. Hanahan, R. Weinberg (2011)Hallmarks of Cancer: The Next Generation
C. Jordan, M. Guzman, M. Noble (2006)Cancer stem cells.
The New England journal of medicine, 355 12
P. Bose, V. Gandhi, M. Konopleva (2017)Pathways and mechanisms of venetoclax resistance
Leukemia & Lymphoma, 58
Purpose of Review Apoptosis results from the interaction between pro- and anti-apoptotic proteins, mediated by BCL-2 homology 3 (BH3) proteins. B cell lymphoma-2 (BCL-2) is an inhibitor of apoptosis which stabilizes the mitochondria, resulting in the prevention of activation of the pro-apoptotic proteins. In addition, BCL-2 is overexpressed in the leukemic stem cell (LSC) population, and its inhibition may lead to selective LSC eradication. Herein, we will discuss the mechanism and rationale of BCL-2 inhibition in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) with an overview of the selective BCL-2 inhibitor venetoclax. Recent Findings Venetoclax has activity against AML and has displayed synergistic activity with hypomethylating agents in the preclinical setting. In the clinical setting, although it has only modest activity as a single agent in relapsed and refractory AML, in the older, treatment-naïve population, in combination with either a hypomethylator or low-dose cytarabine, it is well tolerated with impressive efficacy. In addition, BCL-2 inhibition may also have activity in MDS, and although clinical trials are in their early phases, this may be an effective strategy in both the up-front and relapsed setting. Summary BCL-2 inhibition with venetoclax is well tolerated and active in older patients with newly
Current Hematologic Malignancy Reports – Springer Journals
Published: Jul 7, 2018
Access the full text.
Sign up today, get DeepDyve free for 14 days.